NeoAntigen peptides
Vaccineexperimental
Clinical trial activity
6 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2008 (NCT00995358)
Timeline
Indications
Mechanism of action
- Tumor antigensImmunity, active
immunity, active - tumor antigens
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05475106 | Early Phase 1 (Phase 1) | May 12, 2022 | Instituto de Medicina Regenerativa |
| NCT05667545 | Phase 1 | Jul 1, 2021 | Al Azhar University |
| NCT04509167 | Early Phase 1 (Phase 1) | Aug 10, 2020 | Instituto de Medicina Regenerativa |
| NCT04397926 | Phase 1 | May 30, 2020 | Sun Yat-Sen University |
| NCT04072900 | Phase 1 | Sep 1, 2019 | Central South University |
| NCT00995358 | Phase 2 | Nov 30, 2008 | University of Tokyo, University of Yamanashi |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Instituto de Medicina Regenerativa | Academic/Hospital | 2 | 2 | 1 | 2020 |
| Al Azhar University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Central South University | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Tokyo | Academic/Hospital | 1 | 0 | 1 | 2008 |
| University of Yamanashi | Academic/Hospital | 1 | 1 | 1 | 2008 |
6 organizations
Page 1 / 1